The Polylaminin Race: Brazil's Quest for a Breakthrough in Spinal Cord Treatment

An experimental treatment called polylaminin is generating significant attention in Brazil, with patients traveling from afar and government fast-tracking its approval despite pending clinical trials. Expert caution contrasts public enthusiasm, driven by promising early findings of nerve regeneration, yet safety and efficacy remain unproven.

An experimental treatment for spinal cord injuries, known as polylaminin, is drawing intense interest in Brazil. Patients are traveling even from Mexico to access the small-town laboratory spearheading the research.

The treatment's promise of nerve regeneration has attracted thousands worldwide, leading to some hiring legal help to access the drug.

While the government advances approval, experts urge caution due to the lack of clinical trial proof regarding its safety and effectiveness.